Investigation Launched into Aquestive Therapeutics Following Significant Stock Decline

In a recent development, Schubert Jonckheer & Kolbe LLP has announced an investigation targeting Aquestive Therapeutics, Inc. (Nasdaq: AQST) due to alarming claims about potential misleading statements that may have adversely affected shareholders. Following the company's January 2026 announcement regarding FDA identified deficiencies in its New Drug Application for the drug candidate Anaphylm, its stock experienced a drastic decline of 37%.

On January 9, 2026, the FDA highlighted substantial deficiencies in Aquestive's New Drug Application, which resulted in halted discussions about labeling and post-marketing commitments for Anaphylm. This news provoked a panic among investors, leading to a substantial drop in the company's stock price. A class action complaint has alleged that between June 2025 and January 2026, the company misled investors regarding the likelihood of FDA approval by asserting that everything was on track for the targeted action date set for January 31, 2026.

Schubert Jonckheer’s investigation will delve into the actions taken by the company’s executives and board members in light of these significant allegations. The firm is urging current shareholders of Aquestive Therapeutics to evaluate their options, especially those feeling financially impacted by the recent stock drop. Potential victims of this stock crash are encouraged to explore their legal avenues, which could potentially lead to restitution or compensation.

The San Francisco-based law firm specializes in representing consumers in class action lawsuits and shareholders in actions against corporate executives and directors accused of malpractice. With a growing number of investors raising concerns, this investigation could lead to greater scrutiny of corporate governance at Aquestive.

It’s noted that the allegations against Aquestive Therapeutics not only involve the recent FDA findings but also touch on broader issues within the pharmaceutical industry, particularly around the transparency of drug approvals and ethical compliance. This case highlights the critical importance of communication from companies to their investors and the need for accountability when misstatements potentially lead to significant financial losses.

Shareholders seeking further information can reach out to Schubert Jonckheer through their specialized website dedicated to investors of Aquestive Therapeutics. It’s vital for investors to be proactive in understanding their rights and the possible ramifications of the alleged misrepresentations by the company.

As legal investigations unfold, the implications for Aquestive Therapeutics remain to be seen, but the attention from a law firm of Schubert Jonckheer's stature signifies a serious examination of the company’s practices. Investors need to stay updated while also being prepared for potential outcomes, which could include legal remedies if wrongdoing is substantiated.

This situation prompts a broader discussion about the responsibilities of executives in publicly traded companies to provide accurate representations of their business status and to safeguard the interests of their shareholders. The ongoing developments are a cautionary tale for many investors in the highly volatile pharmaceutical sector.